imidapril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| angiotensin-converting enzyme inhibitors | 1424 | 89371-37-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 5 % | Benet LZ, Broccatelli F, Oprea TI |
| BA (Bioavailability) | 20 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 54 mg/mL | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1993 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cardiac failure | 49.25 | 41.47 | 21 | 536 | 89121 | 63399344 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral infarction | 44.72 | 30.38 | 19 | 867 | 27436 | 34928609 |
| Hepatic function abnormal | 30.44 | 30.38 | 17 | 869 | 44346 | 34911699 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cardiac failure | 67.67 | 28.38 | 41 | 1587 | 154801 | 79587959 |
| Cerebral infarction | 61.66 | 28.38 | 26 | 1602 | 45650 | 79697110 |
| Hepatic function abnormal | 55.80 | 28.38 | 28 | 1600 | 73079 | 79669681 |
| Renal impairment | 49.64 | 28.38 | 34 | 1594 | 157749 | 79585011 |
| Altered state of consciousness | 43.15 | 28.38 | 20 | 1608 | 43802 | 79698958 |
| Interstitial lung disease | 42.00 | 28.38 | 27 | 1601 | 112573 | 79630187 |
| Embolic stroke | 31.56 | 28.38 | 10 | 1618 | 7816 | 79734944 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C09AA16 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, PLAIN ACE inhibitors, plain |
| MeSH PA | D000806 | Angiotensin-Converting Enzyme Inhibitors |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011480 | Protease Inhibitors |
| CHEBI has role | CHEBI:35457 | ACE inhibitor |
| CHEBI has role | CHEBI:35674 | antihypertensive drugs |
| CHEBI has role | CHEBI:50266 | Prodrugs |
| CHEBI has role | CHEBI:49103 | drug metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.49 | acidic |
| pKa2 | 4.83 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Angiotensin-converting enzyme | Enzyme | INHIBITOR | IC50 | 5 | CHEMBL | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| D01549 | KEGG_DRUG |
| 89396-94-1 | SECONDARY_CAS_RN |
| C0165703 | UMLSCUI |
| CHEBI:135654 | CHEBI |
| CHEBI:141520 | CHEBI |
| CHEMBL317094 | ChEMBL_ID |
| DB11783 | DRUGBANK_ID |
| C065166 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5464343 | PUBCHEM_CID |
| 6377 | IUPHAR_LIGAND_ID |
| C078006 | MESH_SUPPLEMENTAL_RECORD_UI |
| 6394 | INN_ID |
| BW7H1TJS22 | UNII |
| 259335 | RXNORM |
| 007791 | NDDF |
| 007792 | NDDF |
| 395741003 | SNOMEDCT_US |
| 395984005 | SNOMEDCT_US |
| 426163004 | SNOMEDCT_US |
| C0246977 | UMLSCUI |
| CHEMBL99701 | ChEMBL_ID |
| 7209 | INN_ID |
| 89371-44-8 | SECONDARY_CAS_RN |
| 5464344 | PUBCHEM_CID |
| 6378 | IUPHAR_LIGAND_ID |
| WUU07Y30IA | UNII |
Pharmaceutical products:
None